Experimental
Therapies: New treatments for hepatitis C including
pre-clinical development that have not yet been studied in humans, and various
drugs that are in phase I, II and III development to treat hepatitis C.
·
General
o
1307. PF-03491390 inhibits liver fibrosis in
patients with chronic hepatitis C virus infection via suppression of
pro-apoptotic caspase-activation. (updated
o
1387. A Hepatitis C T-Cell Vaccine Candidate
Covering HCV Genotype Complexity and HLA Type Diversity (updated
o
1389. Efficacy of Interferon β combined
cyclosporine A treatment in the retreatment of chronic
hepatitis C - Promising aspect of host factor targeting therapy. (updated
o
1397. AM3 inhibits HCV replication through
activation of peripheral blood mononuclear cells.
·
Preclinical trials – new treatment for
hepatitis C that have not yet been tested in humans
o
ANA 598
§
1392. ANA598, a Novel Non-Nucleoside
Inhibitor of HCV NS5B Polymerase, Exhibits Favorable Pharmacokinetic Properties
in Multiple Preclinical Species (updated
o
ME 3738
§
1393. ME3738 inhibits hepatitis C virus
replication by enhancing interferon-β
o
PF-00868554
§
1394. Preclinical Evaluations of
PF-00868554, a Potent Non-nucleoside Inhibitor of the Hepatitis C Virus RNA
Polymerase (updated
·
Clinical Trials – new treatments for
hepatitis C that have been conducted in humans (phase I, II, III, IV)
o
Bavituximab
o
Boceprevir (SCH 503034)
o
GI-5005
§
1304. HCV-Specific Cellular Immunity, RNA
Reductions, and Normalization of ALT in Chronic HCV Subjects after Treatment with
GI-5005, a Yeast-Based Immunotherapy Targeting NS3 and Core: A Randomized,
Double-blind, Placebo Controlled Phase 1b Study (updated
o
GS-9190
o
HCV 796
o
ITMN-191 (R7227)
o
Locteron
o
NTZ
o
R1626
§
1298. A high barrier to resistance may
contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype
1-infected treatment-naive patients R7025 (updated
o
R7025
o
R7128
§
LB9. Antiviral Activity, Pharmacokinetics,
Safety, and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase
Inhibitor, Following Multiple, Ascending, Oral Doses in Patients with HCV
Genotype 1 Infection Who have Failed Prior Interferon Therapy (updated November
12,2007)
o
Telaprevir (VX-950)
§
50.
Telaprevir resistance mutations in patients with hepatitis C who relapsed after
sequential therapy with telaprevir, peg-interferon alfa 2a and ribavirin
o
Thymosin
§
1331. Retreatment of treatment experienced
HCV patients with pegylated interferon alfa-2a and thymosin alpha-1: Pooled
analysis of two randomized controlled trials (updated
o
TMC435350
§
1318. Results Of A Phase I
Placebo-Controlled Trial In Healthy Volunteers To Examine The Safety,
Tolerability And Pharmacokinetics Of The HCV Protease Inhibitor TMC435350 After
Single And Repeated Dosing (updated
§
1390. In Vitro
Activity And Preclinical Pharmacokinetics Of The HCV Protease Inhibitor,
TMC435350.
o
VCH-759
§
LB11. Antiviral activity of the
non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients:Results from a randomized, double-blind, placebo
-controlled, ascending multiple dose study. (updated